Health Technology

Real Time Medical Systems Empowers Clinicians to Drive Value-Based Care Outcomes with Post-Acute Partners at 2024 Spring Managed Care Forum

Retrieved on: 
Thursday, May 2, 2024
Software, General Health, Professional Services, Data Management, Technology, Hospitals, Security, Health Technology, Data Analytics, Nursing, Practice Management, Health, Real, KLAS, HITRUST, Senior, Patient, Infection, Real-time

Real Time Medical Systems (Real Time), the industry leading, KLAS Rated, and HITRUST Certified post-acute analytics solution announced today its participation at the 2024 Spring Managed Care Forum on May 2-3, 2024 in Orlando, FL.

Key Points: 
  • Real Time Medical Systems (Real Time), the industry leading, KLAS Rated, and HITRUST Certified post-acute analytics solution announced today its participation at the 2024 Spring Managed Care Forum on May 2-3, 2024 in Orlando, FL.
  • Joining healthcare executives from the American Association of Integrated Healthcare Delivery Systems (AAIHDS), American Association of Managed Care Nurses (AAMCN), and NAMCP Medical Directors Institute , the Real Time team will be sharing how live data analytics is helping care teams across the continuum drive value-based outcomes.
  • Through the use of post-acute data transparency, providers are reducing avoidable rehospitalizations, detecting early signs of infectious disease, advancing care coordination efforts, and improving patient outcomes.
  • Through risk stratifying patients and supporting collaboration with post-acute care partners, Real Time’s interventional analytics platform is arming clinicians with vital tools – enabling them to get the right patient, the right care, at the right time.”
    Heading to the 2024 Spring Managed Care Forum?

KARL STORZ and Well Lead Medical Announce Exclusive Agreement for Distribution of ClearPetra Stone-Removal System in the U.S.

Retrieved on: 
Thursday, May 2, 2024
Health Technology, Health, Medical Devices, Well, MIT Tech Talk, Urology, Kidney, American Urological Association, Marketing, Cleveland Clinic, MD, PCNL, Gynaecology, FRCSC, Stone, Booth, Master of Science, AUA, KARL, Research institute, Pharmaceutical industry

KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction with KARL STORZ endoscopic visualization devices for comprehensive urinary stone management.

Key Points: 
  • KARL STORZ United States announces an exclusive agreement with Well Lead Medical to offer the ClearPetra suction-evacuation ureteral access sheath in conjunction with KARL STORZ endoscopic visualization devices for comprehensive urinary stone management.
  • “Our strategic collaboration with Well Lead Medical on ClearPetra represents a major step forward in stone management.
  • “The collaboration between Well Lead Medical and KARL STORZ represents a significant milestone in our commitment to advancing endourology.
  • During the show, KARL STORZ will be sponsoring a Tech Talk on May 4, 10:00–10:25 a.m., at Booth #1733.

Cerus Corporation Announces First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Medical Supplies, Health, Medical Devices, Hospitals, Health Technology, General Health, Biotechnology, FDA, Red blood cell, Investment, AUC, Cerus Corporation, Research, Canadian Blood Services, LED, Patient, Platelet, Government, GAAP, Growth, Pharmaceutical industry

The Company expects to report GAAP net loss attributable to Cerus Corporation for the full-year 2024 while also remains committed to adjusted EBITDA breakeven for the full-year 2024.

Key Points: 
  • The Company expects to report GAAP net loss attributable to Cerus Corporation for the full-year 2024 while also remains committed to adjusted EBITDA breakeven for the full-year 2024.
  • R&D expenses for the first quarter of 2024 were $14.5 million, compared to $17.4 million for the first quarter of 2023.
  • Net loss attributable to Cerus Corporation for the first quarter of 2024 was $9.7 million, or $0.05 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $15.6 million, or $0.09 per basic and diluted share, for the first quarter of 2023.
  • As discussed during prior quarters, the Company expects full-year 2024 non-GAAP adjusted EBITDA breakeven, though over the near term, results may not be consistent quarter by quarter.

InfuSystem to Report First Quarter 2024 Financial Results on May 9, 2024

Retrieved on: 
Thursday, May 2, 2024
Other Manufacturing, Medical Devices, Medical Supplies, Hospitals, Health Technology, Manufacturing, Managed Care, Health, Oncology

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue first quarter 2024 financial results on Thursday, May 9, 2024, before the market opens.

Key Points: 
  • InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue first quarter 2024 financial results on Thursday, May 9, 2024, before the market opens.
  • The Company will also conduct a conference call for all interested parties on Thursday, May 9, 2024 at 9:00 a.m. Eastern Time to discuss its financial results.
  • To participate in this call, please dial (800) 285-6670 or (713) 481-1320, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/ .
  • A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (888) 556-3470, replay access code 159874 through Thursday, May 16, 2024.

Pacific Islands Primary Care Association and HealthEfficient Partners with eClinicalWorks to Expand Community Access to Comprehensive Health Center Solutions

Retrieved on: 
Thursday, May 2, 2024
Technology, Hospitals, Health Technology, Software, Practice Management, Other Health, Managed Care, General Health, Health, Data Management, AI, Health information technology, Population health, EHR, Electronic health record, Partnership, Primary health care, Patient, HIT, UDS, Community, Patient satisfaction, Digital divide, HRSA, Nursing

The health centers are participants in the “Pacific Islands Electronic Health Initiative,” a federally funded project led by the Pacific Islands Primary Care Association (PIPCA) and its partner HealthEfficient , a not-for-profit organization based in New York.

Key Points: 
  • The health centers are participants in the “Pacific Islands Electronic Health Initiative,” a federally funded project led by the Pacific Islands Primary Care Association (PIPCA) and its partner HealthEfficient , a not-for-profit organization based in New York.
  • The Pacific Islands Primary Care Association promotes and supports quality primary health care throughout the Pacific Islands.
  • With our revolutionary technology, health centers have access to solutions that will enhance patient engagement, streamline documentation, and help increase access to care.”
    eClinicalWorks offers comprehensive health center solutions , including cloud solutions and integrations with primary care, dental, vision, value-based care, and behavioral health.
  • With access to eClinicalWorks integrated cloud-based solutions, PIPCA’s member health centers are better equipped to provide data-driven care to care to vulnerable populations.

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

Retrieved on: 
Thursday, May 2, 2024
Surgery, Science, Other Health, Veterinary, Nursing, Medical Supplies, Radiology, FDA, Other Science, Pharmaceutical, Diabetes, Research, Optical, Oncology, Mental Health, Medical Devices, Stem Cells, Infectious Diseases, Health Technology, Practice Management, Hospitals, Physical Therapy, Genetics, Managed Care, Fitness & Nutrition, Dental, Clinical Trials, Cardiology, Biotechnology, Alternative Medicine, AIDS, Health, Immunoglobulin G, Automation, ADAS, Safety, Pharmacokinetics, Animal, Primate, Software, Therapy, Litre, Toxicokinetics, Drug development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

Key Points: 
  • Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.
  • The Gyrolab Generic Rodent ADA Kit fills an industry-wide need for a generic assay solution to expedite immunogenicity assessment.
  • Following the introduction of Gyrolab Generic Cyno ADA Kit Reagents, the Gyrolab Generic Rodent ADA Kit Reagents further expand the utility of the Gyrolab platform into earlier drug screening and preclinical phases of development.
  • Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies, commented: “The addition of the Gyrolab Generic Rodent ADA Kit Reagents to our portfolio enhances our offering of ready-to-use kits and solutions for use in drug screening and preclinical development.

Dr. Richard Awdeh, CEO of CheckedUp, Named as MM+M 2024 Pinnacle Award Honoree

Retrieved on: 
Thursday, May 2, 2024
Managed Care, General Health, Health Technology, Health, Point of care, Patient, Medicine, Validation, Multimedia, Point, POC, Condition, Growth, Nursing

CheckedUp announced that its CEO and co-founder, Dr. Richard Awdeh, has been named a 2024 Pinnacle Award honoree by Medical Marketing + Media (MM+M).

Key Points: 
  • CheckedUp announced that its CEO and co-founder, Dr. Richard Awdeh, has been named a 2024 Pinnacle Award honoree by Medical Marketing + Media (MM+M).
  • The 2024 Pinnacle Awards class includes 20 honorees, who hail from a diverse range of health-and wellness-adjacent organizations.
  • View the full release here: https://www.businesswire.com/news/home/20240502068698/en/
    “I am tremendously honored to be part of the 2024 Pinnacle Award class,” said Dr. Awdeh.
  • The Pinnacle Awards are designed to remedy that.”
    The 2024 Pinnacle Awards honorees are profiled in the May print edition of MM+M and will be celebrated at an in-person event on May 2 in New York City.

BobiHealth Launches Personalized Pregnancy Monitoring and Alert System Designed to Revolutionize Maternal Care and Support Health Care Equity

Retrieved on: 
Thursday, May 2, 2024
Baby, Maternity, Technology, Health, General Health, Women, Health Technology, Medical Devices, Apps, Applications, Artificial Intelligence, Mobile, Wireless, Consumer, Mortality, Pregnancy, Safety, Woman, Android, AI, CDC, Gestational hypertension, Heart, Infant, Black, White, Caregiver, Movement, Gestational diabetes, Multimedia, Death, Apple, Algorithm, Knowledge, Medical device

View the full release here: https://www.businesswire.com/news/home/20240502036712/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240502036712/en/
    The BobiHealth app, available for free on the Apple store through August 2024, offers expectant mothers and their caregivers detailed insights into maternal health.
  • Whether it's a potential concern or reassurance to continue monitoring, BobiHealth provides invaluable guidance driven by evidence-based science and AI algorithms.
  • Access to care, costs and potential racial bias in the health care system could contribute to these disparities.
  • Founded in 2023 with a mission to enhance the safety of pregnancy, BobiHealth is poised to revolutionize maternal healthcare with its intelligent monitoring and alerting solutions.

Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29

Retrieved on: 
Thursday, May 2, 2024
Research, Technology, Medical Devices, Genetics, Health Technology, Software, Biotechnology, Hardware, Health, Science, Agilent Technologies

Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2024 after the stock market closes on May 29.
  • In addition, the company will host a conference call to discuss the results at 1:30 p.m. PT.
  • To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website.
  • A recording of the call will also be available on the website for 90 days.

Arcturis and Oxford University Hospitals NHS Foundation Trust announce 3-year programme to deliver highly enriched Real-World Data supporting generation of evidence for the development and approval of novel cancer therapies.

Retrieved on: 
Friday, May 3, 2024
Data Management, Biotechnology, Technology, Professional Services, Health, General Health, Oncology, Health Technology, Data Analytics, Software, Genetics, TVS, Cancer, Partnership, NHS, Real, Informatics, Health care, Research, Pharmacy, OUH, Environment, Thames Valley, Patient, Privacy, Google Images, Biomarker, Confidentiality, Medical imaging

OUH will provide Arcturis researchers with access to its deep, longitudinal anonymised oncology data within the Thames Valley and Surrey Secure Data Environment for healthcare research (TVS SDE).

Key Points: 
  • OUH will provide Arcturis researchers with access to its deep, longitudinal anonymised oncology data within the Thames Valley and Surrey Secure Data Environment for healthcare research (TVS SDE).
  • This innovative approach will facilitate access to anonymised NHS data for approved research projects within an NHS-controlled environment.
  • Kerrie Woods, Director, R&D Clinical Informatics for OUH commented:
    “Arcturis has unique expertise in integrating molecular and clinical data and curating fit-for-purpose regulatory-grade research datasets.
  • This valuable work will help to improve the quality and completeness of the data available for world class research, driving real world impact.